Revvity, MDIC, and NIST Launch Somatic Cancer Reference Standards to Ensure Diagnostic Accuracy
Revvity Launches Next-Generation Somatic Cancer Reference Standards in Collaboration with MDIC and NIST Revvity, Inc. today announced the release of its new, highly characterized Mimix™ Geni™ somatic cancer reference standards,…
City Therapeutics Submits Clinical Trial Application for CITY-FXI
City Therapeutics Submits Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic Targeting Factor XI for the Treatment of Thromboembolic Diseases City Therapeutics, Inc., a pioneering biopharmaceutical company focused on…
Kardigan Reports Positive Phase 2 Results for Ataciguat in Aortic Stenosis
Kardigan Showcases Positive Phase 2 Data for Ataciguat in Moderate Calcific Aortic Valve Stenosis at AHA Scientific Sessions 2025 Kardigan, a cardiovascular-focused biotechnology company working to modernize drug development for…
Onchilles Pharma Publishes ELANE Pathway Study, Advances N17350 With New Funding
Onchilles Pharma Publishes Landmark ELANE Pathway Study, Advances N17350 Toward Clinical Development With New Financing and Strategic Clinical Expertise Onchilles Pharma, a privately held biotechnology company developing a new class…
CrossBridge Bio Named “Best Drug Developer” at 2025 World ADC Awards
CrossBridge Bio Awarded “Best Drug Developer” at the 2025 World ADC Awards, Celebrating Breakthrough Innovation in Dual-Payload ADCs CrossBridge Bio, an emerging biopharmaceutical innovator specializing in the development of next-generation…
Aulos Bioscience Phase 2 Results Show Imneskibart Activity in Melanoma and NSCLC
Aulos Bioscience Unveils Encouraging New Phase 2 Data Highlighting Imneskibart’s Clinical Activity in Melanoma and Non–Small Cell Lung Cancer Aulos Bioscience, a clinical-stage immuno-oncology company advancing next-generation immune-modulating therapies, has…
FASENRA Delays Disease Flares in Phase III HES Trial
AstraZeneca’s FASENRA Demonstrates Statistically Significant Clinical Benefit in Phase III NATRON Trial for Hypereosinophilic Syndrome AstraZeneca has announced positive full results from its pivotal Phase III NATRON clinical trial evaluating…
Indapta Highlights Clinical Activity of Allogeneic NK Therapy in R/R Multiple Myeloma
Indapta Therapeutics Showcases Promising Clinical Activity of IDP-023 Allogeneic g-NK Cell Therapy in Relapsed/Refractory Multiple Myeloma at SITC 2025 Indapta Therapeutics, Inc., a privately held, clinical-stage biotechnology company focused on…
Synthekine Reports Positive Early Phase 1 Results for STK-012 Combo in First-Line PD-L1-Negative NSCLC
Synthekine Unveils Encouraging Early Clinical Results for STK-012 in Combination Therapy for First-Line PD-L1–Negative Non-Squamous NSCLC at SITC 2025 Synthekine Inc., a biotechnology company advancing a new generation of engineered…
Gilead Shares New Findings from Phase 3 ASCENT-07 Trial
Gilead Shares Update on Phase 3 ASCENT-07 Trial Evaluating Trodelvy in HR+/HER2-Negative Metastatic Breast Cancer Gilead Sciences, Inc. (Nasdaq: GILD) has released new clinical findings from its Phase 3 ASCENT-07…
Mirum Highlights LIVMARLI® and Volixibat Data at AASLD Liver Meeting®
Mirum Pharmaceuticals Spotlights Advancements in Rare Liver Disease With New Data From LIVMARLI® and Volixibat Programs at AASLD’s The Liver Meeting® 2025 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biotechnology company…
Biomunex Showcases MAIT Engager Preclinical Data at 2025 SITC
Biomunex to Present Preclinical Data on MAIT Engager Platform at 2025 SITC Annual Meeting Biomunex Pharmaceuticals, an innovative French biopharmaceutical company advancing the next generation of antibody-based immunotherapies, announced that…